Liraglutide vs Semaglutide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Liraglutide vs Semaglutide: Semaglutide has the stronger overall evidence (8.5 vs 7.5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Semaglutide Edges Ahead

Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Liraglutide0 wins

Semaglutide2 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Lir7.5

Liraglutide

Too few graded studiesLimited safety

Sgl8.5

Semaglutide

Too few graded studiesLimited safety

Evidence

Evidence Score

7.5/10

Studies: 436

Meta-analyses: 73

Level: Strong

Evidence Score

Best8.5/10

Studies: 455

Meta-analyses: 134

Level: Very Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies242
Weight managementToo few graded studies124
Cardiovascular outcomesToo few graded studies42

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies197
Weight managementToo few graded studies182
Cardiovascular outcomesToo few graded studies58

Shared outcomes (3)

Outcomes where both Liraglutide and Semaglutide have evidence — compare verdict strength side-by-side.

Blood sugar & glycemic controlToo few graded studies242Too few graded studies197
Weight managementToo few graded studies124Too few graded studies182
Cardiovascular outcomesToo few graded studies42Too few graded studies58

Dosage & timing

Recommended Dosage:

Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: liraglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.
Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.
FDA has warned about COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-daily injection (Victoza for diabetes, Saxenda for weight)

Recommended Dosage:

Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: semaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation.
Post-marketing reports of ileus (severely slowed gut motility).
May worsen pre-existing diabetic retinopathy, attributed to rapid improvement in glucose control — ensure ophthalmologic monitoring in patients with a history of diabetic retinopathy.
Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.
FDA has warned about COMPOUNDED / grey-market semaglutide: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-weekly injection (Ozempic / Wegovy)

Safety

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Shared goals

Manage weightSemaglutide

Liraglutide72/100

Semaglutide88/100

Manage blood sugarSemaglutide

Liraglutide80/100

Semaglutide85/100

Support heart healthSemaglutide

Liraglutide70/100

Semaglutide75/100

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Moderate weight losspositive

Months (titrated over weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

🤢 GI adverse effects (very common)trade-off

Especially during dose escalation

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Substantial weight losspositive

Months (titrated over 16-20 weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

🤢 GI adverse effects (very common)trade-off

Especially during dose escalation

Key studies

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER).

N Engl J Med (2016) · Rct · n=9340

Double-blind cardiovascular-outcomes RCT: 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide or placebo added to standard care, median follow-up 3.8 years.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes).

N Engl J Med (2015) · Rct · n=3731

56-week double-blind RCT in 3,731 adults WITHOUT type 2 diabetes (BMI ≥30, or ≥27 with comorbidities), liraglutide 3.0 mg/day vs placebo plus lifestyle (2:1)

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

JAMA (2015) · Rct · n=846

56-week double-blind RCT in 846 adults with overweight or obesity and type 2 diabetes, liraglutide 3.0 mg, 1.8 mg or placebo (2:1:1), all with diet and activity advice.

All Liraglutide studies

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).

N Engl J Med (2021) · Rct · n=1961

Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).

N Engl J Med (2023) · Rct · n=17604

Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).

N Engl J Med (2016) · Rct · n=3297

Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks

All Semaglutide studies

Frequently asked questions

Is Liraglutide better than Semaglutide?

Semaglutide has a higher evidence score (8.5/10 vs 7.5/10) and wins in 2 of 3 categories.

Is Liraglutide or Semaglutide better for manage weight?

For manage weight, Semaglutide has a higher relevance score (88 vs 72).

Can I take Liraglutide and Semaglutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Liraglutide vs Tirzepatide AREDS2 Formula vs Liraglutide Dulaglutide vs Liraglutide Semaglutide vs Tirzepatide AREDS2 Formula vs Semaglutide Dulaglutide vs Semaglutide

Still deciding between Liraglutide and Semaglutide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Liraglutide details Semaglutide details

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: liraglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.

Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.

FDA has warned about COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: semaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation.

Post-marketing reports of ileus (severely slowed gut motility).

May worsen pre-existing diabetic retinopathy, attributed to rapid improvement in glucose control — ensure ophthalmologic monitoring in patients with a history of diabetic retinopathy.

Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.

FDA has warned about COMPOUNDED / grey-market semaglutide: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Frequently asked questions

Is Liraglutide better than Semaglutide?

Semaglutide has a higher evidence score (8.5/10 vs 7.5/10) and wins in 2 of 3 categories.

Is Liraglutide or Semaglutide better for manage weight?

For manage weight, Semaglutide has a higher relevance score (88 vs 72).

Can I take Liraglutide and Semaglutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.